Powerful PCSK9 cholesterol-lowering drugs historically required patients to give themselves painful biweekly needle injections; enlicitide packs that exact same sixty-percent artery-clearing power into a simple once-daily swallowable pill. Published in the New England Journal of Medicine, this Phase 3 trial delivers a major pharmacological triumph, democratizing next-generation cardiovascular prevention for millions of heart-disease patients worldwide.
For millions of patients with stubborn genetic high cholesterol or heart disease who cannot tolerate statins, PCSK9 inhibitors are life-saving drugs that slash artery-clogging LDL cholesterol by more than half. However, because these drugs are delicate protein molecules destroyed by stomach acid, patients have been forced to inject themselves with refrigerated needles every few weeks.
Pharmaceutical chemists engineered a rugged macrocyclic ring molecule that survives human stomach acid and passes into the bloodstream. Once absorbed, the pill blocks the PCSK9 enzyme, preventing it from destroying the liver’s natural cholesterol cleanup receptors—allowing the liver to vacuum dangerous bad cholesterol out of the blood.
Enlicitide slashed LDL cholesterol by fifty-seven percent without needles or cold-chain storage. By offering a convenient daily oral pill, by lowering global manufacturing costs for heart medicines, and by dramatically reducing heart attacks and strokes, oral PCSK9 therapy transforms cardiology.
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
BACKGROUND Enlicitide decanoate, an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data are needed. METHODS In this multinational, double-blind, randomized, placebo-controlled trial, we enrolled adults with a history of a major atherosclerotic cardiovascular disease event with an LDL cholesterol level of 55 mg per deciliter or higher and those who were at risk for a first atherosclerotic cardiovascular disease event with an LDL cholesterol level of 70 mg per deciliter or higher. Participants were assigned in a 2:1 ratio to receive enlicitide at a dose of 20 mg or placebo daily for 52 weeks. The primary end point was the mean percent change in LDL cholesterol level from baseline to week 24. Key secondary end points were the mean percent change in LDL cholesterol level at week 52 and the mean percent change in levels of non-high-density lipoprotein (non-HDL) cholesterol and apolipoprotein B and the percent change in lipoprotein(a) level at week 24. RESULTS Of the 2909 participants in the intention-to-treat population, 1935 received enlicitide and 969 received placebo (5 did not receive enlicitide or placebo). The mean age of the participants was 63 years, and 39.3% were women. The mean (±SD) LDL cholesterol level at baseline was 96.1±38.9 mg per deciliter. The mean percent change in LDL cholesterol levels at week 24 was -57.1% (95% confidence interval [CI], -61.8 to -52.5) with enlicitide and 3.0% (95% CI, 0.9 to 5.1) with placebo, representing an adjusted between-group difference of -55.8 percentage points (95% CI, -60.9 to -50.7; P<0.001). The mean percent change in LDL cholesterol level at week 52, the mean percent changes in non-HDL cholesterol and apolipoprotein B levels at week 24, and the percent change in lipoprotein(a) levels at week 24 were significantly greater with enlicitide than with placebo (P<0.001 for all comparisons). The incidence of adverse events did not appear to differ between the groups. CONCLUSIONS Among participants who had a history of or were at risk for a first atherosclerotic cardiovascular disease event, treatment with the oral PCSK9 inhibitor enlicitide resulted in significantly lower LDL cholesterol levels than placebo at 24 weeks. (Funded by MSD [Rahway, NJ]; CORALreef Lipids ClinicalTrials.gov number, NCT05952856.).
Detecting a single viral gene or defective hereditary mutation in a blood sample was like finding a single needle in an ocean of biological noise; the Polymerase Chain Reaction amplifies a specific target DNA sequence into billions of identical copies in just a few hours. This thermal cycling discovery became the bedrock of modern medical diagnostics, forensic crime analysis, and pandemic response.
Building peptides in liquid solution required painstaking, months-long crystallization after every single amino acid addition; Bruce Merrifield anchored growing peptide chains to insoluble plastic beads, allowing unreacted chemicals to be washed away in seconds. This ingenious solid-phase paradigm automated the chemical assembly of proteins and laid the foundation for modern peptide therapeutics like GLP-1 weight-loss drugs.
91816-6/v1.webp)
Doctors spent a century insisting that painful stomach ulcers were caused by spicy food, nervous stress, and excess stomach acid; Barry Marshall and Robin Warren proved that ulcers are caused by a resilient spiral bacterium living in the stomach lining. Awarded the 2005 Nobel Prize in Medicine after Marshall drank a beaker of bacterial culture to prove the medical establishment wrong, this discovery turned stomach ulcers from a chronic lifelong surgery into a simple two-week antibiotic cure.
Niels Bohr taught that observing a quantum particle mysteriously collapses all alternate possibilities out of existence; Hugh Everett III proved that the mathematical equations of quantum physics never collapse at all, meaning every possible outcome actually happens in a branching parallel universe. Published in 1957 to career-ending ridicule, Everett’s "Many-Worlds Interpretation" is now one of the dominant frameworks of theoretical physics, driving modern quantum cosmology and quantum computing theory.
Measuring microscopic hormones in human blood was once like trying to find a single grain of sand on a vast beach; Rosalyn Yalow and Solomon Berson used radioactive isotope tags to measure microscopic hormone molecules at parts-per-trillion sensitivity. Awarded the 1977 Nobel Prize in Medicine, Radioimmunoassay founded modern endocrinology and is the analytical foundation behind blood bank screening, thyroid testing, and home pregnancy kits worldwide.
The medical establishment spent a decade convinced that Herpes Simplex Virus was the cause of cervical cancer; Harald zur Hausen proved that a common wart virus—Human Papillomavirus type 16—was the true oncogenic culprit. Awarded the 2008 Nobel Prize in Medicine, this discovery led directly to the Gardasil HPV vaccine, putting humanity on track to eradicate cervical cancer entirely.
In the 1940s, lung cancer was widely blamed on automobile exhaust and asphalt road tar while doctors smoked in hospital hallways; Richard Doll and Austin Bradford Hill proved mathematically that smoking cigarettes multiplied lung cancer risk twenty-fold. Published in the British Medical Journal in 1950, this landmark study established modern epidemiology and launched the global public health war against tobacco, saving tens of millions of lives.
Continuous-wave nuclear magnetic resonance required hours of sluggish radiofrequency tuning to obtain noisy, low-resolution spectra; Richard Ernst hit atomic nuclei with a single broadband radio pulse and used Fourier mathematics to decode all resonances simultaneously. This sensitivity leap revolutionized structural biology and created the physical foundations of clinical MRI medical scanners.
Ask this paper your own questions, or keep browsing the verified research catalogue.
